Oppenheimer Reiterates Outperform on Xylem, Lowers Price Target to $160

Benzinga Newsdesk www.benzinga.com Negative 94.1%

Neg 94.1% Neu 0% Pos 0%

Oppenheimer analyst Bryan Blair reiterates Xylem (NYSE:XYL) with a Outperform and lowers the price target from $165 to $160.